.Nature Medication, Released online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Standpoint requires incorporation of patients with MASLD as well as dimension of liver outcomes in cardio-- kidney-- metabolic trials, when data propose mechanistically conceivable perks and also medical security-- and outlines points to consider for test design as well as regulatory commendation.